Congress to Clamp Down on Health Insurers' Sharply Higher Co-Pays?
-
Font Size:
The health insurance industry just can't seem to resist the urge to anger its policyholders and politicians, giving voters and politicians new reasons to clamp down on the industry's propensity to stick it to its sick customers in an effort to sell more insurance policies.
That the story about how insurers are making drug copays unaffordable for their chronically-ill patients is featured by NY Times means that Congress will rush to fix the problem one way or another. HMO stocks such as Coventry (CVH), Health Net (HNT), Humana (HUM), United Health (UNH) and Wellpoint (WLP) will be depressed even more, and drug companies' earnings and stocks will be depressed until the politicians deal with the issue.
As patients' non adherence to physicians' prescriptions grows due to the higher co-pays imposed by insurers, more will have to be admitted to hospitals, and insurers' non-pharmaceutical claims probably will soar. The NY Times reports that insurers have sharply increased co-pays on private and Medicare patients, making some of the most advanced drugs unaffordable. Impact graphs from the Times: With the new pricing system, insurers abandoned the traditional arrangement that has patients pay a fixed amount, like $10, $20 or $30 for a prescription, no matter what the drug’s actual cost. Instead, they are charging patients a percentage of the cost of certain high-priced drugs, usually 20 to 33 percent, which can amount to thousands of dollars a month.
The system means that the burden of expensive health care can now affect insured people, too. No one knows how many patients are affected, but hundreds of drugs are priced this new way. They are used to treat diseases that may be fairly common, including multiple sclerosis, rheumatoid arthritis, hemophilia, hepatitis C and some cancers. There are no cheaper equivalents for these drugs, so patients are forced to pay the price or do without. Insurers say the new system keeps everyone’s premiums down at a time when some of the most innovative and promising new treatments for conditions like cancer and rheumatoid arthritis and multiple sclerosis can cost $100,000 and more a year.
But the result is that patients may have to spend more for a drug than they pay for their mortgages, more, in some cases, than their monthly incomes.
Disclosure: none
- C.R. Bard, Inc. Q2 2008 Earnings Call Transcript »
- McKesson Corp.F1Q09 (Qtr. End 06/30/08) Earnings Call Transcript »
- Varian Medical Systems, Inc. F3Q08 (Qtr. End 06/30/08) Earnings Call Transcript »
- Vascular Solutions Inc. Q2 2008 Earnings Call Transcript »
- Pfizer, Inc. Q2 2008 Earnings Call Transcript »
Get Seeking Alpha Free Stock Alerts by Email!
Get Free Stock Alerts by Email!
-
Editor's Picks
-
Most Popular
- A Long Housing Boom Won't Yield to a Brief Recovery
- Why Congress Blames Index Speculators
- What Are the Prospects for Stagflation?
- State Street Launches 10 Ex-U.S. Sector ETFs
- Eisai Victorious Over Teva and Dr. Reddy’s in Aciphex Compound Patent Case
- Financials Future Still Uncertain
- Full list of Editor's Picks »
- As WaMu, Wachovia Ready Earnings, Comparisons to Wells, USB Are Telling »
- Apple F3Q08 (Qtr End 6/28/08) Earnings Call Transcript »
- Three Stocks To Be Held To Infinity and Beyond »
- Crazy Dividends »
- Apple Investors Nervous as Earnings Call Approaches »
- Wall Street Breakfast: Must-Know News »
- Historic Financial Collapse Underway? »
- Mother of All Short Squeezes? »
- China Poised to Pounce on U.S. Coal Suppliers »
- Is Natural Gas Down for the Count? »
- Barron's Goes Bullish on Banks, Again »
-
Long Ideas
-
Short Ideas
-
Cramer's Picks
- Dollar Back? - Fast Money Recap (7/23/08)
- Terex: Overlooked Bargain
- EBay is a Not Com – Cramer’s Lightning Round (7/23/08)
- Buy Costco, Get Sirius -- Cramer’s Stop Trading! (7/23/08)
- Intuitive Surgical's Q2: A Lesson in Errors of Perception
- Chevron: Good Choice for Conservative Growth Investor
- Pfizer Beats: Recommended at or Below $18
- Illumini, Intuitive: This Healthcare Outperformance Brought to You by the Letter 'I'
- Cynosure: Growth Expected as Sales Go Global
- More Bad News for the Anti-Ethanol Crowd
- Full list of Long Ideas »
- Get True Religion - Cramer's Lightning Round (7/22/08)
- Principal Financial Group Vulnerable to Commercial Real Estate Softening?
- Increases in Shorting, Only for Some
- Is a Ban on Short Financial ETFs on the Horizon?
- Is There a More Efficient Shorting Tactic?
- Short Oil as a Long Investment
- Ford's Financial Services Business About to Enter the Red
- Educational and Training Services Are An Excellent Short Opportunity
- Short Selling: Others Want Protection Too
- The SEC's Campaign Against Naked Shorting: Misguided or Right On?
- Full list of Short Ideas »
- EBay is a Not Com – Cramer’s Lightning Round (7/23/08)
- Buy Costco, Get Sirius -- Cramer’s Stop Trading! (7/23/08)
- Soup Target; Cramer's Mad Money (7/22/08)
- Get True Religion - Cramer's Lightning Round (7/22/08)
- Copper Down Low - Cramer's Stop Trading! (7/22/08)
- Banks Hit Bottom – Cramer’s Mad Money (7/21/08)
- Ends In X - Cramer's Stop Trading! (7/21/08)
- Great American Companies – Cramer’s Lightning Round (7/21/08)
- Market Rotation Bolsters Financials - Fast Money Recap (7/18/08)
- For Everything, Wind - Stop Trading! (7/17/08)
- Full list of Cramers Picks »
Most Popular Feeds
-
ETFs
-
US Market
-
Long Ideas
-
Alt. Energy
- Full list of feeds »
Hedge Fund Jobs
Job Seekers:
- Search jobs by category
- Get job alerts by email or live feed
- Apply online
Employers
- See all recruitment options
- Get applications online or by email



This article has 4 comments:
The supposition that this will cause more inpatiant care has obviously been thought through by the insuance companies and if they have estimated wrong it will be to their advantage to change.
Government heathcare has not worked anywhere in the world and anyone who thinks they will get more care at less cost from the government has not studied the results of political management of healthcare or any other industry.
Almost all those expensive drugs that are available to us have been developed in the USA.
Congress' solution will surely not be the one that makes the most sense. But the industry plan is probably to sit back, wait for Congress to act and then hope they can derail that action.
The industry should spearhead solutions.